J Bone Metab.  2014 Aug;21(3):223-226. 10.11005/jbm.2014.21.3.223.

Intravenous Zoledronate for a Patient with Paget's Disease

• Kim KC

• KMID: 2286293
• DOI: http://doi.org/10.11005/jbm.2014.21.3.223

Abstract

Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for treatment of osteoporosis, have been the most effective agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.

Keyword

Bone density conservation agents; Diphosphonates; Osteitis deformans

MeSH Terms

Bone Density Conservation Agents
Bone Resorption
Diphosphonates
Female
Humans
Middle Aged
Osteitis Deformans
Osteoclasts
Osteogenesis
Osteoporosis
Bone Density Conservation Agents
Diphosphonates